Compare Abrdn Physical Platinum Shares ETF (PPLT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs TransMedics Group Inc — how do they compare? Abrdn Physical Platinum Shares ETF trades at $17.1, while TransMedics Group Inc trades at $85.89 (market cap $3.06B). Which is the better fit depends on your goals.
| PPLT | TMDX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $25.23 | $150.42 |
52-Week Low | $12.38 | $61.99 |
Market Cap | — | $3.06B |
Enterprise Value | — | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT (abrdn Platinum ETF Trust) trades at $16.46, down 0.24% with a bullish technical signal from moving averages. The ETF tracks physical platinum prices, which have lagged behind gold and silver's recent rally. Recent news highlights platinum's potential catch-up trade opportunity as price ratios suggest potential mean reversion. Technical indicators show mixed signals with neutral oscillators but strong trend strength from ADX.
The outlook suggests potential upside as platinum seeks to close its performance gap with other precious metals. Key risks include commodity price volatility and macroeconomic factors affecting industrial demand. Investment opportunity lies in platinum's historical tendency for mean reversion and its dual role as both precious metal and industrial commodity.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
